RxDoctor Payments Data

Aneela Kazi, MD

Child & Adolescent Psychiatry · Washington, DCNPI 1720241011

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. 2023 is the largest year on record at $1,045, 3.0 times the $349 reported in 2019. Among child & adolescent psychiatry clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,864in general payments, 2019–2025

Across 129 payments — averaging $22.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$585
  • Lundbeck LLC$428
  • AbbVie$420
  • Johnson & Johnson$357
  • Otsuka America Pharmaceutical, Inc.$308
  • Neurocrine Biosciences, Inc.$282
  • plus $483 from 4 others

What the payments were for

  • Food & beverage$2,864100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,864 in reported general payments places this provider in the 95th percentile of 21 child & adolescent psychiatry providers in District of Columbia.

See all child & adolescent psychiatry providers in District of Columbia

Medicare billing

Part B allowed, 2024
$371,799
Medicare patients
1,018
Services billed
2,788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Quetiapine Fumarate207$5,184
Escitalopram Oxalate251$4,318
Lorazepam395$2,979
Duloxetine Hcl71$2,416
Olanzapine45$2,268
Risperidone99$1,714
Trazodone Hcl193$1,401
Sertraline Hcl89$1,333
Mirtazapine63$1,183
Buspirone Hcl68$1,158
Aripiprazole34$961
Divalproex Sodium59$895
Gabapentin57$865
Bupropion XlBupropion Hcl20$781
Venlafaxine Hcl ErVenlafaxine Hcl26$700

Paid to pharmacies, not to this prescriber.

Other child & adolescent psychiatry in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →